Data Supplement

• Supplemental Figures -

  Figure S1. Immunofluorescence imaging of C12FDG in A) HN30 and B) HN12 cells after senescence induction by 5 μM cisplatin. 

  Figure S2. ABT-263 has minimal cytotoxicity on non-senescent cells or proliferative
  recovering cells from senescence.

  Figure S3. BCL-XL is the primary target for ABT-263-induced senolysis.

  Figure S4. Cisplatin, ABT-263 treatment alone or in combination did not result in significant Neutropenia.
  

  Figure S5. Cisplatin, ABT-263 treatment alone or in combination did not result in significant levels of
  DNA double strand breaks measured by γ-H2AX levels. p > 0.05 All quantitative graphs are mean ± SD
  from at least three independent experiments.

  Figure S6. Animal experiments diagram.
  

• Supplemental Video 1A -

  Video S1. Live cell imaging of A) Vehicle treated. Note that control cells are included to compare morphology and cellular behavior in between control and senescent cells
  
  
  
  
  

• Supplemental Video 1B -

  Video S1. Live cell imaging of  B) 5 μM cisplatin-treated HN30 cells at Days 5-6. Note that control cells are included to compare morphology and cellular behavior in between control and senescent cells.
  

• Supplemental Video 1C -

  Video S1. Live cell imaging of   C) Day 10-12 (recovered cells). Time lapse images of HN30 cells were
  taken with 15 min intervals. Note that control cells are included to compare morphology
  and cellular behavior in between control and senescent cells.